136 related articles for article (PubMed ID: 2446076)
1. Differences in vasodilating action between ketanserin, a 5-HT2-serotonergic receptor antagonist, and terazosin, an alpha 1-adrenoceptor antagonist, in anesthetized rabbits.
Ikeda K; Takata M; Tomoda F; Mikawa M; Iida H; Sasayama S
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S69-72. PubMed ID: 2446076
[TBL] [Abstract][Full Text] [Related]
2. An investigation of the effects of intravenous injection of the 5-hydroxytryptamine 2 receptor antagonists ketanserin and LY 53857 on blood pressure in anesthetized spontaneously hypertensive rats.
Docherty JR
J Pharmacol Exp Ther; 1989 Feb; 248(2):736-40. PubMed ID: 2537414
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.
Persson B; Gradin K; Pettersson A; Hedner T
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S22-4. PubMed ID: 2459509
[TBL] [Abstract][Full Text] [Related]
4. The alpha-adrenergic receptor blocking effect of ketanserin and the interaction between alpha-adrenergic and S2-serotonergic receptor blockade.
van der Starre PJ; Reneman RS
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S54-61. PubMed ID: 2459516
[TBL] [Abstract][Full Text] [Related]
5. Alpha-adrenergic and serotonergic mechanisms in the human digit.
Coffman JD; Cohen RA
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S49-53. PubMed ID: 2459515
[TBL] [Abstract][Full Text] [Related]
6. Effects of antagonists of 5-hydroxytryptamine on blood pressure in the anesthetised spontaneously hypertensive rat.
Docherty JR; Warnock P
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S59-61. PubMed ID: 2446073
[TBL] [Abstract][Full Text] [Related]
7. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.
Cohen ML; Schenck KW; Kurz KD
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S25-9. PubMed ID: 2459510
[TBL] [Abstract][Full Text] [Related]
8. Potential vascular alpha1-adrenoceptor blocking properties of an array of 5-HT receptor ligands in the rat.
Centurión D; Mehotra S; Sánchez-López A; Gupta S; MaassenVanDenBrink A; Villalón CM
Eur J Pharmacol; 2006 Mar; 535(1-3):234-42. PubMed ID: 16545797
[TBL] [Abstract][Full Text] [Related]
9. Renal hemodynamic responses to 5-hydroxytryptamine (5-HT): involvement of the 5-HT receptor subtypes in the canine kidney.
Shoji T; Tamaki T; Fukui K; Iwao H; Abe Y
Eur J Pharmacol; 1989 Nov; 171(2-3):219-28. PubMed ID: 2576001
[TBL] [Abstract][Full Text] [Related]
10. Serotonin-induced vasoconstriction in dog kidney.
Takahashi T; Hisa H; Satoh S
J Cardiovasc Pharmacol; 1992; 20(5):779-84. PubMed ID: 1280741
[TBL] [Abstract][Full Text] [Related]
11. alpha-Adrenoceptor subtypes mediating regional kidney blood flow responses to renal nerve stimulation.
Eppel GA; Lee LL; Evans RG
Auton Neurosci; 2004 May; 112(1-2):15-24. PubMed ID: 15233926
[TBL] [Abstract][Full Text] [Related]
12. Differences in the chronic hypotensive mechanism of action of ketanserin in spontaneously hypertensive and Wistar-Kyoto rats.
Balasubramaniam G; Lee HS; Mah SC
J Hypertens; 1994 Jan; 12(1):7-14. PubMed ID: 8157947
[TBL] [Abstract][Full Text] [Related]
13. Evidence for two populations of 5-hydroxytryptamine receptors in dog basilar artery.
Frenken M
J Pharmacol Exp Ther; 1989 Jul; 250(1):379-87. PubMed ID: 2545865
[TBL] [Abstract][Full Text] [Related]
14. Specificity of the serotonergic antagonist ketanserin.
Stott DJ; Robertson JI; Ball SG
J Hypertens Suppl; 1985 Dec; 3(3):S191-3. PubMed ID: 2856702
[TBL] [Abstract][Full Text] [Related]
15. Differences in the acute and chronic antihypertensive mechanism of action of ketanserin in spontaneously hypertensive rats.
Balasubramaniam G; Lee HS; Mah SC
J Pharmacol Exp Ther; 1993 Jan; 264(1):129-34. PubMed ID: 8093720
[TBL] [Abstract][Full Text] [Related]
16. Central 5-hydroxytryptamine (5-HT) receptors in blood pressure regulation.
Dabiré H
Therapie; 1991; 46(6):421-9. PubMed ID: 1819150
[TBL] [Abstract][Full Text] [Related]
17. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
Hosie J; Stott DJ; Robertson JI; Ball SG
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S86-8. PubMed ID: 2446081
[TBL] [Abstract][Full Text] [Related]
18. Ketanserin: haemodynamic effects and mechanism of action.
Schalekamp MA; Woittiez AJ; Wenting GJ; van den Meiracker AH; Man in 't Veld AJ
J Hypertens Suppl; 1986 Apr; 4(1):S7-12. PubMed ID: 2871144
[TBL] [Abstract][Full Text] [Related]
19. Inhibition by intraventricular microinfusion of ketanserin of the cardiovascular responses to peripheral administration of methoxamine in rats.
Mollace V; De Francesco EA; Fersini G; Nisticò G
Funct Neurol; 1991; 6(2):101-6. PubMed ID: 1655588
[TBL] [Abstract][Full Text] [Related]
20. Importance of central nervous system serotonin-1A receptors for mediating the hypotensive effect of urapidil.
Mandal AK; Kellar KJ; Friedman E; Pineo SV; Hamosh P; Gillis RA
J Pharmacol Exp Ther; 1989 Nov; 251(2):563-70. PubMed ID: 2530339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
